Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors.

Abstract

Immune checkpoint inhibitors (CPIs) reverse immune suppression that is thought to allow malignant growth. Despite remarkable efficacy in a subset of cancers, their use is accompanied by immune-related adverse events, including endocrinopathies such as hypophysitis, thyroid dysfunction, diabetes, and adrenalitis. These conditions are heterogenous, with differing incidence across CPI types, but are unified by the acuity and extremity of tissue-specific organ failure. Their occurrence may be associated with beneficial tumor control. Further understanding of the risk factors and mechanisms of these endocrine immunotoxicities can help optimize CPI use as well as improve understanding of spontaneous autoimmune diseases.

• Authors: Zoe Quandt, Arabella Young, Ana Luisa Perdigoto, Kevan C Herold, Mark S Anderson
• Journal: Annual review of medicine (Annu Rev Med) Vol. 72 Pg. 313-330 (01 27 2021) ISSN: 1545-326X [Electronic] United States
• PMID: 32886542 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Immune Checkpoint Inhibitors

Topics

• Autoimmune Diseases (chemically induced, immunology)
• Autoimmunity (drug effects)
• Endocrine System Diseases (chemically induced, immunology)
• Humans
• Immune Checkpoint Inhibitors (adverse effects)